| Version | Summary | Created by | Modification | Content Size | Created at | Operation |
|---|---|---|---|---|---|---|
| 1 | Dean Liu | -- | 2457 | 2022-10-13 01:46:00 |
Sinopharm BBIBP-CorV, also known as the Sinopharm COVID-19 vaccine, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina , Bahrain, Egypt, Morocco, Pakistan , Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19. Based on data provided to WHO, the vaccine shows 78.1% efficacy against symptomatic COVID-19 in phase III trials, (21 cases in vaccinated group vs. 95 cases in placebo group). Real-world test-negative analysis in Bahrain (based on 14 days post 2nd dose) indicated a vaccine effectiveness of 90% for adults aged 18-59, and 91% for those 60 year old or older. In December 2020, the UAE previously announced interim results showing 86% efficacy. While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures. BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia, Africa, South America, and Europe. Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021. By May, Sinopharm had supplied 200 million doses. On 7 May 2021, the World Health Organization approved the vaccine for use in COVAX.